1、 夯实医药基本盘,布局医美构建业绩增长新动能 !#$%&600200.SH()*+2023!3 1#!#$%&()*+,-./0 http:/ 2!#$%&()#$1*+%&!#$%&2,*34567(#64/1!#$!#$%&()*+,)*+,!#$!#$%-.-./$$%0 0/!#$%&89#+,/1 资料来源:万得,信达证券研发中心 !#$%&:#;,#/1!#$%&!#$%&()*+,-.#/01234%5*(678(97:;?4A5 BC(+D.E4F.5 C(B+GH I.JK4A5(67 DLM4F%5 N6(C*资料来源:万得,信达证券研发中心 123456789
2、:;4?ABCDEFGGFHHEEGGGH4IJKLCEFGGGMEGENM4O4444PCQRSTRUVWXYZRXUZZ_44a4567894?ABCDEFGGFHHEEGGGM4IJKLCEbNGEbNNEcM4O4444PCdUXefSWEYZRXUZZ_4-ghijklmno pqrst4DupvwqxquD4pyzxs|cBEB OACEGGGME 1!#$%!#$%&()&()*+*+,-./012345,-./01234567089:;?A67089:;?A1 1!/1()*)+,-=?AB=?ABC C1 1!0/1!#$%&()*+,-./#$%&()*+,-./01234
3、56 7889:/;:?ABC3D0123EF)#GH?IJ/KL:M6NO.PQ?RSDGHTUVWXY-Z.D)#-.Y_&abcde/fg7h:ijDklm)nopqr)#O.stuvDwxy#$z(|/;|?C3D01236A?)*O./fg78:GH:“”fgfgfgf9Di)#)*?A“”/GH6fgf7:45)*.23*GHD;-Z#u-?D()*/(-)*-.%/(-)*-.%/7 7Zfgf7:“”*D DP ;?;zO3D6 fgf:+fZfgf7:7f)D D lm!#4$D%&()*+u,-.D;6/7U0123f456789:;?ABC+uDE9gF GHIJKL/P
4、;?MNOz3DPR QRS TUVCD-MW6 fgf:X:+/%6+uY,CZ -D-+UMW_GH.abC/c-c-d15cMef/d15cMef/0123g-md1zhij()*AB,Z/7Zfgff:k%l0mnopqr3us%$tu-vw4d1xyDzus%$tu-vw23*ij()*d5|fZfgff:h cMMm?ij|()*usd4/aD! fgff:I“”DGY6 fgf#u-DM 7kg%sZ#sm3#D-Z:ZZy/PGH4k-Zu-m?-./jB$-m_D0123)#k-.%YDA,mus#s?R d1./fgff:P9DD)#.sV;DGH/U DGH&?
5、#.MWj1/y/y/GH)#.DU D)*.!#$%&ic-Di-*MW6 fgf:9+ZD4GH.a?bC/%6aD fgfffgf9:GH56$78g9 Zffk Zfk8 D$gh Zg Z79 Dc$g7fZgg Zgfg/fgf:7 bDN fgfffgf9:S”$kk Z789 Z9/!D#b-$%/!#$!%#$!$!#$#$#$$%#$(!#()!#(#!#(!#(!#(*!#(+,-./0*#!#$%&()*+,-./0 http:/ 3 KL&/KL&/)#Z)*O.()KLUO*E#-KLm+.,-.KL/1 11 1!/1重要财务指标重要财务指标 2020A
6、2021A 2022E 2023E 2024E 营业总收入(百万元)!#$%!#&%!()%$#*%$#*%增长率 YoY%+!,$-%+&,!)-%#,$.-%!,*#-%$(,&!-%归属母公司净利润(百万元)+&(.,)!%$,#$%+),%*,*(%!),.!%增长率 YoY%+),#-%!(),)-%+)#$,$-%!*,*-%*),$)-%毛利率%*(,#)-%$,*-%$,(.-%*$,(-%*.,(-%净资产收益率ROE%+$#,)-%!,$-%+),#-%!,&-%#,)$-%EPS(摊薄)(元)+(,#!%(,(*%+(,!$%(,(&%(,$(%市盈率 P/E(倍)+